DWTX

Company Overview — What Does Dogwood Therapeutics, Inc. Do?

Dogwood Therapeutics Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and Virios Therapeutics, Inc. The company changed its name to Dogwood Therapeutics Inc. in 2024. Dogwood Therapeutics Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia. Dogwood Therapeutics, Inc. (DWTX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Greg Duncan and employs approximately 5 people. With a market capitalization of $71M, DWTX is one of the notable companies in the Healthcare sector.

Dogwood Therapeutics, Inc. (DWTX) Stock Rating — Avoid (April 2026)

As of April 2026, Dogwood Therapeutics, Inc. receives a Avoid rating with a composite score of 21.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.DWTX ranks #4,339 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Dogwood Therapeutics, Inc. ranks #793 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DWTX Stock Price and 52-Week Range

Dogwood Therapeutics, Inc. (DWTX) currently trades at $2.02. The stock gained $0.04 (2.0%) in the most recent trading session. The 52-week high for DWTX is $9.50, which means the stock is currently trading -78.7% from its annual peak. The 52-week low is $2.60, putting the stock -22.3% above its annual trough. Recent trading volume was 41K shares, suggesting relatively thin trading activity.

Is DWTX Overvalued or Undervalued? — Valuation Analysis

Dogwood Therapeutics, Inc. (DWTX) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.90x, versus the sector average of 2.75x.

At current multiples, Dogwood Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Dogwood Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Dogwood Therapeutics, Inc. (DWTX) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -43.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -36.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DWTX Debt, Balance Sheet, and Financial Health

Dogwood Therapeutics, Inc. has a debt-to-equity ratio of 20.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.76x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $10M.

DWTX has a beta of 0.38, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Dogwood Therapeutics, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Dogwood Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Dogwood Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-7.13. Net income for the quarter was $-33M. Operating income came in at $-26M.

In FY 2025, Dogwood Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-7.13. Net income for the quarter was $-34M. Operating income came in at $-28M.

In Q3 2025, Dogwood Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-8.20. Net income for the quarter was $-16M. Operating income came in at $-16M.

In Q2 2025, Dogwood Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.99. Net income for the quarter was $-4M. Operating income came in at $-4M.

Over the past 8 quarters, Dogwood Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DWTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DWTX Dividend Yield and Income Analysis

Dogwood Therapeutics, Inc. (DWTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DWTX Momentum and Technical Analysis Profile

Dogwood Therapeutics, Inc. (DWTX) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

DWTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Dogwood Therapeutics, Inc. (DWTX) ranks #793 out of 838 stocks based on the Blank Capital composite score. This places DWTX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DWTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DWTX vs S&P 500 (SPY) comparison to assess how Dogwood Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

DWTX Next Earnings Date

No upcoming earnings date has been announced for Dogwood Therapeutics, Inc. (DWTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DWTX? — Investment Thesis Summary

The quantitative profile for Dogwood Therapeutics, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 34/100) increases portfolio risk.

In summary, Dogwood Therapeutics, Inc. (DWTX) earns a Avoid rating with a composite score of 21.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DWTX stock.

Related Resources for DWTX Investors

Explore more research and tools: DWTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DWTX head-to-head with peers: DWTX vs AZN, DWTX vs SLGL, DWTX vs VMD.